Postoperative extremity gangrene in a patient with type 2 diabetes taking SGLT2 inhibitors: A case report

RATIONALE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been approved and marketed since March 2013. The proportion of patients with type 2 diabetes (T2D) taking SGLT2 inhibitors is increasing. The perioperative adverse effects of SGLT2 inhibitors, especially euglycemic diabetic ketoacidos...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Yun Chin, Liu, Kuan-Lin, Lee, Chia-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
3300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078377/
https://www.ncbi.nlm.nih.gov/pubmed/33879720
http://dx.doi.org/10.1097/MD.0000000000025590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078377/
https://www.ncbi.nlm.nih.gov/pubmed/33879720
http://dx.doi.org/10.1097/MD.0000000000025590

Ejemplares similares